|
|
Article: NEUROCRINE BIOSCIENCE LAUNCHES INSOMNIA DRUG PHASE III TRIALS.(Phase III trial of non-benzodiazepine compound to treat chronic insomnia)(Product Development)(Brief Article)
- Article from:
- BIOWORLD Today
- Article date:
- November 19, 2001
- Author:
CopyrightCOPYRIGHT 2001 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
As promised, Neurocrine Biosciences Inc. began the first pivotal Phase III trial of NBI-34060, a non-benzodiazepine compound that acts against chronic insomnia through a specific site of the GABA-A receptor.
The 500-patient trial is a randomized, double-blind, parallel-group, multicenter study to evaluate the safety of two doses of NBI-34060 in its immediate-release form, at about 40 medical sites in the U.S. and Europe.
Two more pivotal Phase III trials with immediate-release NBI- 34060, licensed by Neurocrine from DOV Pharmaceutical Inc., of Hackensack, N.J., are planned to begin shortly.
Neurocrine has deals with other firms such as ...